Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration?

Trends in Pharmacological Sciences

Volumn 19, Issue 11, 1998, Pages 447-451

  Tzschentke, Thomas M ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BROMOCRIPTINE; DIZOCILPINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BEHAVIOR; CATALEPSY; CONDITIONING; DRUG EFFECT; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIZATION;

EID: 0031727629     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(98)01255-3     Document Type: Article

References (67)

1. Collingridge G. L., Singer W. Trends Pharmacol. Sci. 11:1990;290-296.
2. Willetts J., Balster R. L., Leander J. D. Trends Pharmacol. Sci. 11:1990;423-428.
3. Macrae J. R., Scoles M. T., Siegel S. Br. J. Addiction. 82:1987;371-380.
4. Stewart J., Badiani A. Behav. Pharmacol. 4:1993;289-312.
5. Karler R.et al. Life Sci. 45:1989;599-606.
6. Karler R.et al. Brain Res. 537:1990;76-82.
7. Trujillo K. A., Akil H. Science. 251:1991;85-87.
8. Kalivas P. W. Drug Alcohol Depend. 37:1995;95-100.
9. Sorg B. A., Kalivas P. W. Semin. Neurosci. 5:1993;343-350.
10. Trujillo K. A., Akil H. Drug Alcohol Depend. 38:1995;139-154.
11. Wolf M. E. Prog. Neurobiol. 54:1998;679-720.
12. Ida I., Asami T., Kuribara H. Jpn. J. Pharmacol. 69:1995;83-90.
13. Jeziorski M., White F. J., Wolf M. E. Synapse. 16:1994;137-147.
14. Kalivas P. W., Alesdatter J. E. J. Pharmacol. Exp. Ther. 267:1993;486-495.
15. Karler R., Calder L. D., Bedingfield J. B. Psychopharmacology. 115:1994;305-310.
16. Kim H-S., Jang C-G. Brain Res. Bull. 44:1997;221-227.
17. Kim H-S.et al. Brain Res. Bull. 40:1996;201-207.
18. Ohmori T.et al. Pharmacol. Biochem. Behav. 48:1994;587-591.
19. Wolf M. E., Jeziorski M. Brain Res. 613:1993;291-294.
20. Wolf M. E., Khansa M. R. Brain Res. 562:1991;164-168.
21. Druhan J. P., Jakob A., Stewart J. Eur. J. Pharmacol. 243:1993;73-77.
22. Stewart J., Druhan J. P. Psychopharmacology. 110:1993;125-132.
23. Carey R. J.et al. Pharmacol. Biochem. Behav. 51:1995;901-908.
24. Carlezon W. A. Jr., Mendrek A., Wise R. A. Synapse. 20:1995;1-9.
25. Ranaldi R., Neklesa T., Wise R. A. Soc. Neurosci. Abstr. 23:1997;1091.
26. Tzschentke T. M., Schmidt W. J. Behav. Pharmacol. 7:1996;169-184.
27. Tzschentke T. M., Schmidt W. J. Behav. Brain Res. 84:1997;99-107.
28. Wise R. A., Mendrek A., Carlezon W. A. Jr. Synapse. 22:1996;362-368.
29. Segal D. S., Kuczenski R., Florin S. M. Behav. Neurosci. 109:1995;532-546.
30. Wedzony K., Czyrak A. Brain Res. 657:1994;351-356.
31. Wedzony K., Golembiowska K., Klimek V. Brain Res. 625:1993;333-336.
32. Wolf M. E., White F. J., Hu X-T. Behav. Pharmacol. 4:1993;429-442.
33. Vanderschuren L. J. M. J., Schoffelmeer A. N. M., De Vries T. J. Life Sci. 61:1997;PL427-PL433.
34. Carlezon W. A. Jr., Wise R. A. Brain Res. 620:1993;339-342.
35. Pierce R. C., Meil W. M., Kalivas P. W. Psychopharmacology. 133:1997;188-195.
36. Ranaldi R., Bauco P., Wise R. A. Brain Res. 760:1997;231-237.
37. Ranaldi R., French E., Roberts D. C. S. Psychopharmacology. 128:1996;83-88.
38. Wise R. A., Bozarth M. A. Psychol. Rev. 94:1987;469-492.
39. Kuribara H.et al. Psychopharmacology. 108:1992;271-275.
40. Haracz J. L.et al. Life Sci. 57:1995;2347-2357.
41. Gancher S., Mayer A. Brain Res. 682:1995;63-68.
42. Pinheiro-Carrera M.et al. Behav. Neurosci. 109:1995;34-42.
43. Tolliver B. K.et al. Psychopharmacology. 126:1996;191-198.
44. Ujike H.et al. Life Sci. 50:1992;1673-1681.
45. Gnegy M. E., Hewlett G. H. K., Pimputkar G. Brain Res. 734:1996;35-42.
46. Wolf M. E., White F. J., Hu X-T. J. Neurosci. 14:1994;1735-1745.
47. Zhang Y.et al. Neuropharmacology. 36:1997;325-334.
48. Pierce R. C., Kalivas P. W. Brain Res. Rev. 25:1997;192-216.
49. Marek P.et al. Brain Res. 547:1991;77-81.
50. Tiseo P. J., Inturrisi C. E. J. Pharmacol. Exp. Ther. 264:1993;1090-1096.
51. File S. E., Fernandes C. Pharmacol. Biochem. Behav. 47:1994;823-826.
52. Koff J. M.et al. Pharmacology. 55:1997;217-227.
53. Shoaib M., Stolerman I. P. J. Psychopharmacol. 10:1996;214-218.
54. Wise R. A., Leeb K. Behav. Pharmacol. 4:1993;339-349.
55. Cox J.et al. Psychobiology. 22:1994;156-166.
56. Tzschentke T. M., Schmidt W. J. Neurosci. Lett. 193:1995;37-40.
57. De Montis M. G.et al. Behav. Pharmacol. 6:1995;562-567.
58. Gambarana C.et al. Behav. Phamacol. 9:1998;61-68.
59. Schmidt W. J. Amino Acids. 14:1998;5-10.
60. Schmidt W. J., Bubser M. Pharmacol. Biochem. Behav. 32:1989;621-623.
61. Jackson A., Koek W., Colpaert F. C. Behav. Pharmacol. 3:1992;415-421.
62. Siegel S. Behav. Neurosci. 102:1988;228-232.
63. Hoffman D. C., Wise R. A. Psychopharmacology. 107:1992;277-284.
64. Dai H., Carey R. J. Behav. Brain Res. 62:1994;149-156.
65. Willetts J., Balster R. L. J. Pharmacol. Exp. Ther. 251:1989;627-633.
66. Koek W., Kleven M. S., Colpaert F. C. Behav. Pharmacol. 6:1995;590-600.
67. Vanderschuren L. J. M. J.et al. Trends Pharmacol. Sci. 19:1998;79-81.